Lose weight & keep it off for adults and children aged ≥12 years with obesity, or some adults with overweight and weight-related medical problems.

Jan 24, 2025 · One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday ...

By Ludwig Burger and Stine Jacobsen (Reuters) - One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks ...

Jan 20, 2025 · Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

Jan 21, 2025 · Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight loss effects the drug is known for.

Wegovy (semaglutide) injection 2.4 mg is indicated for chronic weight management for adults with obesity and to reduce the risk of major adverse cardiovascular events in adults with obesity or overweight and cardiovascular disease. Read Important Safety and Prescribing Info, including Boxed Warning.

Jan 17, 2025 · A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest Eli Lilly’s rival GLP-1 drug Zepbound may still have an edge over Wegovy.

Wegovy ® is the only GLP-1 RA proven to sustain ~15% mean weight loss at 2 years

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side effects.

Jun 4, 2021 · Across the trials in people without type 2 diabetes, an average weight loss of 17-18% 1 sustained over 68 weeks was reported for people with obesity treated with Wegovy™. Wegovy™ demonstrated a safe and well-tolerated profile across the programme, with the most common adverse events being gastrointestinal.